25 results
To assess the pharmacokinetics of various cytotoxic agents (carboplatin, cisplatin, cytarabine, dactinomycin, daunorubicin, dinutuximab bèta, doxorubicin, etoposide, methotrexate, vincristine or thiotepa) and kinase inhibitors (ALK, RAS pathway,…
The aim of this study is to identify whether it is possible to safely discontinue treatment in stable RRMS patients who have shown no evidence of active inflammation in the years prior to inclusion in terms of the return of inflammatory disease…
This strategy will result in a reduction reduce the incidence of major adverse cardiovascular events (MACE) defined as death or non-fatal myocardial infarction and appear more efficient than care as usual.
To determine whether CDT in high-risk PE relative to systemic thrombolysis is:- more effective and safer in terms of a reduction of the composite endpoint on all-cause mortality and adverse events defined as treatment failure, major&…
In this explorative study, we aim to: Analyze neoantigens expressed on different tumors of CMMRD patients, to identify more possible target antigens for DC vaccination studies and to select the antigens that are most frequent. …